March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Economic Evaluation of ExPRESS versus Trabeculectomy
Author Affiliations & Notes
  • Yvonne M. Buys
    Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada
  • Hussain Patel
    Department of Ophthalmology, University of Auckalnd, Auckland, New Zealand
  • Lilach Drori Wagschal
    Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel
  • Graham E. Trope
    Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships  Yvonne M. Buys, Alcon Canada (R), I-MED, Alcon Canada (F); Hussain Patel, I-MED, Alcon Canada (F); Lilach Drori Wagschal, I-MED, Alcon Canada (F); Graham E. Trope, I-MED, Alcon Canada (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1399. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yvonne M. Buys, Hussain Patel, Lilach Drori Wagschal, Graham E. Trope; Economic Evaluation of ExPRESS versus Trabeculectomy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1399.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : ExPRESS miniature glaucoma shunt is an alternative filtration procedure to trabeculectomy. The aim of this study was to compare the one year cost differences between the two operations.

Methods: : Subjects enrolled in a randomized prospective study comparing ExPRESS to trabeculectomy with one year follow-up were included in the analysis. Surgical cost difference and the one year post-operative costs including follow-up visits, additional procedures and medications were determined for each subject. Costs were based on the Ontario Health Insurance Plan and the Ontario Drug Benefit Formulary. Comparisons between treatment groups were made using Wilcoxon rank-sum test for costs and chi-square for success (IOP 5-18 mmHg and 20% reduction for baseline without medication). The incremental cost-effectiveness ratio (ICER) was calculated as the ratio of mean surgical and post-operative cost differences divided by surgical success rate differences between the 2 groups at 1 year. All results are reported in Canadian dollars.

Results: : 43 subjects with one year follow-up were included in the analysis (23 ExPRESS, 20 trabeculectomy). There was no statistically significant difference in success rates between the groups; 15 (65%) ExPRESS vs 11 (55%) trabeculectomy, p=0.49. The ExPRESS device had a net surgical cost of $956 greater than trabeculectomy. There was no significant difference in the overall mean post-operative cost (median [interquartile range]) between the ExPRESS ($486 [337, 822]) and trabeculectomy ($610 [305, 820], p = 0.88). There was no significant difference in cost of follow up visits ($303 [276, 358] vs $317 [276, 386], p = 0.75), additional procedures ($183 [0, 366] vs $183 [0, 366], p = 0.69) or glaucoma medication ($0 [0, 68] vs $0 [0, 91], p = 0.80) for ExPRESS vs trabeculectomy respectively. Overall, ExPRESS had a mean one year total cost of $991 greater per case than trabeculectomy. The mean ICER was $9913 per 1-year success gain.

Conclusions: : This study demonstrates that the ExPRESS device is associated with greater surgical cost compared to trabeculectomy. For the province of Ontario if trabeculectomies were all switched to ExPRESS, the incremental cost would be $1,800,000 for the first year and for our department over $200,000.

Clinical Trial: : http://www.clinicaltrials.gov NCT01263561

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×